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Abstract
Background: Skin and soft tissue infections (SSTIs) are a leading cause for hospitalizations in the United States. Few
studies have addressed the appropriateness of antibiotic therapy in the management of SSTIs without complicating
factors. We aimed to determine the appropriateness of antibiotic treatment duration for hospitalized adult patients
with uncomplicated SSTIs.
Methods: This was a retrospective analysis performed at two academic medical centers in Pittsburgh, Pennsylvania
on patients aged 18 years and older with primary ICD-9 code for SSTIs admitted August 1st, 2014–March 31st, 2015.
The primary outcome was the appropriateness of antibiotic treatment duration for uncomplicated SSTIs. Secondary
objectives included the appropriateness of antibiotic agent spectrum, duration of inpatient length of stay (LOS),
utilization of blood cultures and advanced imaging modalities, and re-hospitalization for SSTI within 30 days of
discharge from the index admission.
Results: A total of 163 episodes were included in the cohort. The mean duration of total antibiotic therapy was 12.
6 days. Appropriate duration was defined as receipt of total antibiotic duration of less than 10 days and occurred in
20.2% of patients. Twenty eight percent of patients received antibiotics for greater than 14 days. Seventy three (44.
8%) patients received greater than 24 h of inappropriate extended spectrum gram-negative coverage; 65 (39.9%)
received anaerobic coverage.
Conclusions: In the majority of patients, treatment duration was excessive. Inappropriate broad spectrum antibiotic
selection was utilized with regularity for SSTIs without complicating factors. The management of uncomplicated
SSTIs represents a significant opportunity for antimicrobial stewardship.
Keywords: Cellulitis, Skin and soft tissue infection, Subcutaneous abscess, Antibiotic utilization
Background
Skin and soft tissue infections (SSTIs) are the second most
common type of infections leading to hospitalization in
the United States and are becoming increasingly more
prevalent [1, 2]. Hospitals have experienced a 71% increase
in the rate of hospitalizations due to SSTIs recently, and
these infections are associated with significant healthcare
costs [2–5]. Given the substantial impact these infections
play in healthcare consumption, it is imperative that
evidence-based strategies be developed and implemented
to optimize patient outcomes and utilization of healthcare
resources while limiting the unintended consequences of
unnecessary antibiotic use. Given the rising plague of anti-
microbial resistance, strategies to limit the utilization of
our limited armamentarium of antimicrobial agents are
greatly needed. Given their breadth of effect and signifi-
cant impact on morbidity and mortality, multidrug
resistant bacteria are considered one of the largest threats
to public health and national security by numerous prom-
inent organizations including the Institute of Medicine,
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the Center for Disease Control and Prevention Task Force
on Antimicrobial Resistance, and the Infectious Disease
Society of America (IDSA) [6–9]. In its 2013 annual report
on global risks, the World Economic Forum concluded
that “arguably the greatest risk…to human health comes
in the form of antibiotic-resistant bacteria” [10].
Current evidence has demonstrated that 5–7 days
of antimicrobial therapy is adequate for clinical cure
of uncomplicated SSTIs [11–14]. Despite this, treat-
ment duration in real life settings is inappropriately
long, with prolonged courses of up to 2 weeks or
more commonly prescribed [15–20]. The predominant
pathogens causing uncomplicated SSTIs are aerobic
gram-positive organisms, namely Staphylococcus aur-
eus (S. aureus) and β-hemolytic streptococcal species
[15, 21–28]. Despite this, patients are frequently
treated with broad spectrum antibiotic therapy with
activity against aerobic gram-negative organisms and
anaerobic bacteria [15, 16, 18–20]. The appropriate
use of antimicrobials is critical as unnecessary
utilization is intricately associated with patient harm
due to increased drug resistance, adverse drug events/
toxicity, and collateral damage including Clostridium
difficile (C. difficile) infection [6–10, 29–32]. Despite
the burden of SSTIs on their contribution to overall
antibiotic use in hospitalized patients, knowledge of
current antibiotic prescribing practices is limited. Fur-
ther studies evaluating the details of antibiotic agent
spectrum and duration of therapy for SSTIs without
complicating factors are needed in order to properly
develop targeted initiatives in order to optimize anti-
biotic utilization for this disease state.
The purpose of this retrospective cohort study was to
assess the appropriateness of antibiotic duration and
spectrum for SSTIs in patients without complicating
factors and identify opportunities for antimicrobial stew-
ardship through a thorough descriptive analysis of the
evaluation, treatment, and outcomes among a cohort of
patients hospitalized for uncomplicated SSTIs at two
large teaching facilities.
Methods
Study setting and population
Allegheny General Hospital (AGH) is a 631 bed qua-
ternary care teaching facility with approximately
22,000 inpatient admissions yearly. The Western
Pennsylvania Hospital (WPH) is a 317 bed commu-
nity based teaching hospital with nearly 6,800 in-
patient admissions annually. Both facilities are located
in Pittsburgh, Pennsylvania and are members of the
Allegheny Health Network (AHN). The evaluation
was approved and granted exempt status from the
AHN Institutional Review Board as it was deemed
Quality Assessment/Quality Improvement.
Study design
We identified patients discharged from AGH and WPH
from August 1st, 2014 through March 31st, 2015 with a
primary diagnosis of SSTI using International Classifica-
tion of Diseases, Ninth Revision (ICD-9), coding data.
The search codes included cellulitis and cutaneous ab-
scess (681), other cellulitis and abscess (682), acute
lymphadenitis (683), other infections of skin and sub-
cutaneous tissue (686), and erysipelas (035). All patients
with one of these primary ICD-9 codes were identified
and electronically extracted via our Quality Intelligence
department. For patients with multiple hospitalizations
at AGH and WPH for SSTI during the study period,
each episode was reviewed and included for analysis. En-
counters limited to the Emergency Department were not
included. Demographic information, admission and dis-
charge dates, and length of inpatient hospitalization
were extracted electronically via our Quality Intelligence
department. Utilizing a standardized data collection in-
strument, study investigators (TLW, LC, CIK, MJB,
MAM, DNB, MAM, NHCT) verified the discharge
diagnosis and obtained information regarding patient
comorbidities, microbiologic data, radiographic studies,
inpatient and outpatient antimicrobial therapy, and sub-
sequent inpatient clinical encounters at AGH and WPH
during the 30 days following hospital discharge via re-
view of the patients’ electronic medical record and daily
progress notes written in the patients’ paper medical
record. Inpatient antibiotic therapy was determined via
review of the electronic medication administration rec-
ord. Outpatient antibiotic therapy was determined via
review of the electronic medication reconciliation form
in each patient’s transition of care document.
Patients were excluded for age less than 18 years,
transfer from an outside hospital, left against medical
advice (AMA), death during index hospitalization, or
presence of a concomitant bacterial infection that re-
quired antibiotic therapy. For the purposes of the study
aim, the term “uncomplicated” was used to describe
cases of SSTI where there were no known traditional
risk factors for infection due to gram-negative rods or
anaerobic bacteria. Patients were excluded if they were
associated with any of the following: management in an
intensive care unit (ICU), peri-rectal involvement, peri-
orbital involvement, associated with human or animal
bite, odontogenic source of infection, associated with
diabetic ulceration or chronic underlying ulceration, sur-
gical wound infection, traumatic aquatic injury, associ-
ated with intravenous (IV) illicit drug use, concern for
necrotizing infection, associated with osteomyelitis, pres-
ence of retained infected foreign body, presence of
bacteremia, and presence of neutropenia or severe cell-
mediated immunodeficiency. Severe immunodeficiency
was defined as use of chronic immunosuppressive
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therapy at the time of admission (equivalent of > 10mg
prednisone daily), human immunodeficiency virus (HIV)
with cluster of differentiation 4 (CD4) cell count less
than 350 per cubic millimeter, active malignancy with
receipt of systemic chemotherapy within the 30 days
prior to index admission, and receipt of prior solid organ
transplant or hematopoietic stem cell transplantation.
This definition of uncomplicated SSTI is similar to that
used in prior studies [15, 17–20].
Study outcomes definitions
All endpoints were specified prior to the evaluation. The
primary outcome of interest was to determine the ap-
propriateness of antibiotic treatment duration for SSTIs
in hospitalized patients without complicating factors.
Treatment duration of ten days or longer was defined as
inappropriate. This definition is consistent with that
used in prior real world evaluations [15, 18–20]. Dur-
ation of therapy was defined as the cumulative number
of calendar days during which an antibiotic was adminis-
tered in the inpatient setting or an antibiotic was pre-
scribed to be administered as an outpatient following
discharge. When calculating calendar days of therapy,
the assumption was made that patients would initiate
the outpatient antibiotic regimen on the day of
discharge.
Secondary objectives included the appropriateness of
antibiotic agent spectrum of coverage, the duration of in-
patient length of stay (LOS), utilization of blood cultures
and advanced imaging techniques via computed tomog-
raphy (CT) scan or magnetic resonance imaging (MRI),
and re-hospitalization for SSTI to AGH or WPH within
30 days of discharge from the index admission. Utilization
of greater than 24 h of antibiotics with extended gram-
negative activity, extended anaerobic activity, and anti-
pseudomonal activity was defined as inappropriate unless
the patient had a gram negative rod or anaerobic organism
isolated.
Organisms (excluding coagulase-negative staphylococci,
diphtheroids, Micrococcus, and Proprionibacterium acnes)
were considered to be the etiology of purulent SSTIs when
cultured from purulent drainage or an abscess cavity. As
needle aspirates and punch biopsies are not routinely
performed for cellulitis at AGH or WPH, cases of non-
purulent SSTIs were not included in the evaluation of mi-
crobiologic etiology.
Antibiotics with extended gram-negative activity were
defined as aztreonam; colistin; tigecycline; 3rd, 4th and
5th generation cephalosporins; β-lactam/β-lactamase in-
hibitor combinations (amoxicillin/clavulanate, ampicillin/
sulbactam, piperacillin/tazobactam); carbapenems (ertape-
nem, meropenem); and fluoroquinolones (ciprofloxacin,
levofloxacin, moxifloxacin).
Antibiotics with extended anaerobic activity were de-
fined as β-lactam/β-lactamase inhibitor combinations,
carbapenems, metronidazole, and tigecycline.
Antibiotics with anti-pseudomonal activity were de-
fined as aztreonam, cefepime, ceftazidime, ciprofloxacin,
colistin, levofloxacin, meropenem, and piperacillin/
tazobactam.
Data analysis
Differences between the AGH and WPH cohorts in the
continuous variables of age and length of stay were
assessed using the two sample t-test. P < 0.05 was con-
sidered significant. Differences between the AGH and
WPH cohorts in the categorical variables of race, site of
infection, presence of purulence, treatment duration,
antibiotic agent spectrum, and utilization of blood cul-
tures and advanced imaging modalities were assessed
using Fisher exact. P < 0.05 was considered significant.
Stata statistical software, version 12, was used for data
analysis.
Results
Two hundred eighty four patients with a principal dis-
charge diagnosis of acute bacterial skin and skin struc-
ture infection during the project period were initially
identified by ICD-9 codes. After manual review of the
electronic health record, 121 (42.6%) patients were ex-
cluded from the analysis secondary to transfer from an
outside hospital (38 [13.4%]), left against medical advice
(16 [5.6%]), odontogenic infection (15 [5.3%]), human or
animal bite (12 [4.2%]), intravenous drug use (17 [6%]),
osteomyelitis (8 [2.8%]), surgical wound (8 [2.8%]), nec-
rotizing infection (7 [2.5%]), diabetic and chronic ulcer-
ation (7 [2.5%]), immunocompromised host (5 [1.8%]),
peri-orbital involvement (4 [1.4%]), peri-rectal involve-
ment (4 [1.4%]), management in an ICU (4 [1.4%]), pres-
ence of a retained foreign body (4 [1.4%]), and active
malignancy (2 [0.7%]). Some of the patients were ex-
cluded for more than one characteristic described above.
No patients were excluded due to death or presence of
bacteremia.
The final cohort included 163 (57.4%) unique episodes.
The mean age was 55.3 (SD 19.2) years with the majority
of patients being male 84 (51.5%) and Caucasian 132
(80.9%) (Table 1). The most common site of infection
was the leg in 110 (67.5%) patients. Purulence was noted
in 49 (30.1%) patients. A bacterial organism was isolated
in 47 (28.8%) of patients. The main organism on culture
was S. aureus with methicillin-susceptible S. aureus
(MSSA) isolated in 11 (23.4%) and methicillin-resistant
S. aureus (MRSA) in 10 (21.3%) (Fig. 1).
Appropriate duration of less than 10 days of total anti-
biotic therapy occurred in only 20.2% (33/163) of pa-
tients. Patients received 10-14 days of total antibiotic
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therapy 51.5% (84/163) of the time, and 28.2% received
antibiotics for greater than 14 days (Table 2). The mean
duration of therapy was 12.6 days and this was very
similar between facilities (Fig. 2). The mean hospital
length of stay was 3.7 days.
Seventy three (44.8%) patients received greater than
24 h of extended spectrum gram-negative coverage;
65 (39.9%) received greater than 24 h of anaerobic
coverage; and 28 (17.2%) received greater than 24 h
of unnecessary anti-pseudomonal coverage. Duration
of therapy and inappropriate use of broad spectrum
therapy were similar between the two facilities
(Table 2).
The 30-day re-admission rate for the entire cohort was
7.4% (12/163) with 8.3% (10/120) and 4.7% (2/43) of pa-
tients being re-admitted to AGH and WPH, respectively.
Re-admissions secondary to recurrent SSTI occurred in
3.5% (6/163) of patients with all six re-admissions occur-
ring at AGH. Of the 12 patients who were re-admitted
within 30 days, 2 received less than 10 days of total anti-
biotic therapy originally, while 10 of the 12 patients re-
ceived 10 days or more of total antibiotic therapy. The
rates of 30 day re-admissions were similar between the
group of patients who received less than 10 days of ther-
apy (6.0%) and those who received 10 days or more of
therapy (7.7%).
Of the total cohort of 163 patient episodes, 127
(77.9%) had blood cultures collected. Twenty nine pa-
tients (17.8%) in the total cohort received a CT scan,
while 13 (8.0%) received an MRI. In total, 25.8% of pa-
tients received one of these advanced imaging
modalities.








Mean Age (SD), years 55.6 (19.2) 54.6 (19.3) 55.3 (19.2) .77
Male, n (%) 66 (55.0) 18 (41.9) 84 (51.5) .16
Race, n (%) .87
Caucasian 97 (80.8) 35 (81.4) 132 (80.9)
African American 19 (15.8) 6 (14.0) 25 (15.3)
Other 4 (3.3) 2 (4.7) 6 (3.7)
Site of infection, n (%) .07
Leg 85 (70.8) 25 (58.1) 110 (67.5)
Arm 27 (22.5) 9 (20.9) 36 (22.1)
Trunk 3 (2.5) 3 (7.0) 6 (3.7)
Face 3 (2.5) 2 (4.7) 5 (3.1)
Other 2 (1.7) 4 (9.4) 6 (3.7)
Purulence, n (%) 37 (30.8) 12 (27.9) 49 (30.1) .85
Mean length of stay (SD), days 3.8 (2.5) 3.3 (2.7) 3.7 (2.6) .25
AGH Allegheny General Hospital, SD = standard deviation, WPH Western Pennsylvania Hospital
p value represents comparison between study sites
0 2 4 6 8 10 12
Gram-negative organisms, 3 (6.4)
Mixed gram-positive & gram-negative organisms, 5
(10.6)
Other gram-positive organisms, 4 (8.5)
Streptococci, 6 (12.8)
Polymicrobial gram-positive cocci, 8 (17.0)
MRSA, 10 (21.3)
MSSA, 11 (23.4)
Wound Culture Isolates (%) 
(n = 47) 
Fig. 1 Wound culture isolates. SSTIs skin and soft tissue infections, MSSA methicillin-susceptible Staphylococcus aureus, MRSA methicillin-resistant
Staphylococcus aureus
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Discussion
Treatment duration of 10 days or more was exceeded in
the majority of patients, and we were quite surprised to
learn that only 20.2% of patients received an appropriate
duration of less than 10 days of total antibiotic therapy,
while nearly a third of patients received greater than two
weeks of therapy. While our findings are consistent with
those of previous studies demonstrating that the median
duration of antimicrobial therapy for hospitalized pa-
tients with cellulitis and cutaneous abscess was nearly
two weeks [15–20], this remains startling given that the
IDSA guidelines recommend 5 days of therapy with the
caveat of extending the duration of therapy for patients
who fail to improve after 5 days [12]. This recommenda-
tion is supported by a randomized trial of the treatment
of cellulitis which demonstrated that 5 days of therapy
was as effective as 10 days, although a paucity of patients
required inpatient management [11]. While there is
sparse data otherwise regarding the duration of therapy
for hospitalized patients with uncomplicated SSTIs, the
available evidence suggests these patients can be safely
treated with short courses of antibiotics [13, 14, 17, 33].
Schuler and colleagues aimed to decrease the duration
of antibiotics prescribed in children hospitalized for un-
complicated SSTIs by utilizing quality improvement
methods. They accomplished this aim by increasing pre-
scriptions for short courses of therapy, defined as 7 days
or less, at discharge. There were 641 admissions for un-
complicated SSTIs over a 23 month period. The propor-
tion of children discharged with 7 days or less of
antibiotics increased from a baseline median of 23%–
74%. Differences in the proportion of children who








Appropriate treatment duration, n (%) .74
Less than 10 days 22 (18.3) 11 (25.6) 33 (20.2)
Inappropriate treatment duration, n (%) .99
10 to 14 days 63 (52.5) 21 (41.9) 84 (51.5)
More than 14 days 35 (29.2) 11 (25.6) 46 (28.2)
Inappropriate broad spectrum antibiotics
for > 24 h, n (%)
Gram-negative coverage 52 (43.3) 21 (48.8) 73 (44.8) .59
Anaerobic coverage 46 (38.3) 19 (44.2) 65 (39.9) .59
Anti-pseudomonal coverage 21 (17.5) 7 (16.3) 28 (17.2) .99
AGH Allegheny General Hospital, WPH Western Pennsylvania Hospital



























Duration of inpatient antibiotic
therapy
Duration of outpatient antibiotic
therapy
















AGH WPH Total Cohort
Fig. 2 Antibiotic treatment duration. AGH = Allegheny General Hospital, IV intravenous route of administration, PO oral route of administration, SD
Standard Deviation, WPH Western Pennsylvania Hospital
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experienced treatment failure or recurrence before and
after project initiation were not significant [17]. Jenkins
and co-investigators implemented an institutional guide-
line to standardize and streamline the evaluation and
treatment of inpatient SSTIs in order to optimize anti-
biotic utilization. This intervention led to a significant re-
duction in median duration of antibiotic therapy from 13
days to 10 days without an increase in clinical failure [33].
The diagnosis of SSTIs is based upon morphologic fea-
tures of the lesions and the clinical setting. Cultures of
needle aspirates are not indicated in routine care [12].
However, data from five series in the 1980s using needle
aspiration elucidated common pathogens, with S. aureus
and β-hemolytic streptococci accounting for the vast
majority of infections [21–25]. Two studies in the late
1980s found the yield of punch biopsies to be superior
to needle aspirates [23, 25]. In cases where a microbio-
logic etiology was identified, gram-positive cocci were
present in all but one case [23, 25]. More recent studies
continue to demonstrate that β-hemolytic streptococci
and S. aureus continue to be the primary causes of un-
complicated cellulitis and cutaneous abscesses, compris-
ing up to 97% of positive culture results [15, 28].
Additionally, the IDSA practice guidelines for the diag-
nosis and management of skin and soft tissue infections
recommend the use of narrow spectrum antibiotics tar-
geting only gram-positive pathogens for cases of uncom-
plicated SSTIs [12]. In our cohort, the term
“uncomplicated” was used to define patients with SSTI
who did not have traditional risk factors for infection
due to gram-negative rods or anaerobic bacteria. Despite
this, in our current evaluation where we excluded pa-
tients with known risk factors for SSTIs due to gram-
negative and anaerobic organisms, we found that nearly
half of our patients with uncomplicated SSTIs still re-
ceived inappropriate therapy with extended gram-
negative coverage and a similar number received
extended anaerobic coverage. Our findings are similar to
those reported elsewhere in the literature [15, 16].
Cultures of blood are unnecessary in typical cases of
cellulitis, according to the IDSA guidelines [12]. Less
than 5% of patients with cellulitis have positive blood
cultures [21, 34, 35]. A retrospective analysis of blood
cultures in over 500 patients with community-acquired
cellulitis by Perl and co-investigators [35] found a rele-
vant isolate in only 2% of blood cultures obtained, indi-
cating that blood cultures were not likely to be cost
effective for most patients with cellulitis. Per the IDSA
guidelines, “blood cultures should be obtained…for pa-
tients with malignancy, severe systemic features (such as
high fever and hypotension), and unusual predisposing
factors, such as immersion injury, animal bites, neutro-
penia, and severe cell-mediated immunodeficiency” [12,
21]. In our current analysis, we aimed to include only
patients without risk factors for gram negative or anaer-
obic infections. Therefore, we excluded patients with
malignancy on chemotherapy, neutropenia, severe cell-
mediated immunodeficiency, immersion injuries, and
animal bites. We also aimed to include only patients
without severe infection, so we excluded patients treated
in an intensive care unit, concern for necrotizing infec-
tion and with deeper space infection. In our cohort of
included patients, none had fever of greater than 39°
Celsius and none had hypotension requiring vasopressor
support. Therefore, no patients in our evaluation met
criteria to have blood cultures obtained; despite this,
blood cultures were collected in greater than three-
quarters of our patients. Furthermore, none of the 121
patients who met exclusion criteria for our study had
positive blood cultures, either. Additionally, radiographic
examination is unnecessary in most cases of uncompli-
cated SSTIs [34]. Plain film radiographs and CT offer
limited value except when the clinical setting suggests a
subjacent osteomyelitis. Notwithstanding this, over a
quarter of patients in our cohort received advanced im-
aging with CT or MRI. These are not cost-effective prac-
tices for patients with SSTI and represent potential
opportunities to decrease resource utilization.
This evaluation has several important limitations. First,
it was a retrospective analysis where case finding was re-
liant on ICD-9 coding from hospital discharge data, and
this strategy may have led to underestimation of the true
number of hospitalized patients with uncomplicated
SSTIs at our institutions. Additionally, post-discharge
data analysis was limited to re-admissions to AGH and
WPH. Visits to other inpatient facilities, urgent care
centers, and physicians’ outpatient offices may have been
missed, leading to an inability to determine rates of
treatment failure or the need to extend or re-introduce
antibiotic therapy. We were also unable to assess com-
pliance with outpatient antibiotics. Additionally, our in-
clusion criteria were intentionally selected to only
include those hospitalized patients with SSTIs without
complicating factors. Therefore, we cannot comment
upon those patients with SSTIs with complicating fac-
tors. Lastly, duration of therapy was calculated via calen-
dar days of administration. This may potentially lead to
longer calculated total duration compared to a method
utilizing defined daily doses or hours of therapy
administered.
Our evaluation has numerous strengths as well. Our
study focused upon two different centers with different
patient populations and different medical care providers.
The results were very similar between the facilities and
are in line with the findings in other studies [15, 16].
Our findings demonstrate that inappropriate use of anti-
biotics in the management of SSTIs, both in duration
and spectrum, was pervasive in a community hospital as
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well as in a large academic quaternary care center. This
suggests that an opportunity for improved SSTI manage-
ment exists at both type of facilities. Additionally, given
our extensive exclusion criteria, we were able to analyze
a homogenous patient population focusing only upon
hospitalized patients with SSTI without traditional risk
factors for infection with gram negative rods or anaer-
obic bacteria.
There is a paucity of literature examining the appro-
priateness of antibiotic spectrum and duration for hospi-
talized adults with uncomplicated SSTI in real world
clinical practice [15, 16, 18, 33]. Other studies of uncom-
plicated SSTIs have focused upon antibiotic appropriate-
ness in pediatric patients [17, 20] and in adult patients
in ambulatory care settings [19]. Our current evaluation
adds to the growing body of evidence demonstrating
that the management of hospitalized adult patients with
uncomplicated SSTIs represents an opportunity to sig-
nificantly reduce antimicrobial use by reducing the dur-
ation of therapy in addition to promoting the use of
narrow spectrum therapy targeting aerobic gram-
positive organisms only.
Jenkins and colleagues demonstrated that implementa-
tion of a clinical practice guideline for inpatient cellulitis
and cutaneous abscess led to shorter durations of more
targeted antibiotic therapy without adversely impacting
clinical cure rates [33]. They demonstrated a decrease
from 13 days to 10 days for median duration of total anti-
biotic therapy, while showing fewer patients received anti-
microbial agents with broad aerobic gram negative activity
(66% versus 36%; P < 0.001) and broad anaerobic activity
(76% versus 49%; P < 0.001) [33]. Pasquale et al demon-
strated that the addition of formal guidance via prospect-
ive audit with feedback by an antimicrobial stewardship
program can reduce the use of hospital resources includ-
ing broad spectrum antibiotic therapy, hospital length of
stay, and readmission rates [36]. Their interventions re-
sulted in a reduction in inpatient length of stay from 6.2
days to 4.4 days (P < 0.001) while reducing the 30 day re-
admission rate from 16.7% to 6.5% (P = 0.05) [36]. Given
the high rates of inappropriate use of antibiotics in terms
of both spectrum of therapy and duration of treatment,
uncomplicated SSTI management represents an ideal tar-
get for enhanced antimicrobial stewardship. Given these
findings, our Antimicrobial Stewardship Program (ASP) at
each institution implemented a bundled initiative to
optimize the management of uncomplicated SSTIs by im-
proving prescribing practices. The bundle included (1) an
educational lecture presented to Internal Medicine resi-
dency house staff, Internal Medicine medical staff, the de-
partment of Hospitalist medicine, and the Division of
Infectious Diseases; (2) the creation of an SSTI institu-
tional clinical decision making algorithm which was dis-
tributed to medical staff and house staff via our yearly
Antimicrobial Guide available in both print and electronic
format; and (3) real-time prospective audit of the manage-
ment of patients with uncomplicated SSTIs by the ASP
team with direct oral feedback regarding recommended
management changes. Assessment of the impact of this
bundled approach is ongoing.
Conclusions
In summary, uncomplicated SSTIs are a common cause
of hospitalizations. Antibiotic therapy is frequently of ex-
cessive duration and unnecessarily broad. Optimizing
the use of antibiotics for this disease state is a necessity
given the ongoing C. difficile epidemic and the rise of
antimicrobial resistance. An antimicrobial stewardship
program offers the potential to enhance the use of re-
sources and outcomes for patients with uncomplicated
SSTIs.
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